

Kidney Care for Primary Care: Trying to Keep it Simple

Dr. John Pawlovich, FCFP November 30, 2013 Family Physician Forum, Vancouver, BC

ALE

Disclosures

• None



Objectives

- Review the role of Primary Care
- Review Classification of CKD
- Risk Factors
- Early Detection
- Who to Refer
- Take Home Points





Why is Primary Care Important in CKD Management?



CKD : What the primary care provider needs to know

- Chronic Kidney Disease is common
- CKD does not usually progress to end stage disease in most patients
- CKD is associated with CVD, diabetes and other chronic conditions
- · Dialysis is a terminal illness!



The problem

- Chronic Kidney Disease
 - Perceived as complex and difficult
 - Associated with other clinical conditions
 - Cardiac disease
 - Diabetes
 - Depression
 - Rarity of dialysis and transplant
 patients in general practice
 Changing paradigm and identification
 of early CKD







Classification

The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI ™)

Kidney Disease: Improving Global Outcomes (KDIGO)



Definition of Chronic Kidney Disease 2002/ 2008 KDOQI, KDIGO

- Sustained reduction in kidney function or evidence of kidney damage (>3 mo)
- Staging system based on eGFR with some modifications based on presence of albuminuria

| | Description | GFR (mL per min per 1·73 m²) |
|----|---|---|
| - | At risk | ≥60 (with risk factors for chronic kidney disease) |
| 1 | Kidney damage with normal or increased GFR | ≥90 |
| 2 | Kidney damage with mildly diminished GFR | 60-89 |
| 3* | Moderately reduced GFR | 30-59 |
| 4 | Severely decreased GFR | 15-29 |
| 5 | End-stage renal disease (kidney failure) | <15 |
| | | |



What's New?



| | DEFINITIO | ON OF CKD |
|----------|--|---|
| | KDOQI 2002 | KDIGO 2012 |
| | <pre>CKD is defined as either : •Kidney damage; or •GFR <60 mL/min/1.73 m² for ≥3 months</pre> | Definition remains intact |
| | CKD is classified mainly by GFR category | CKD is classified by: Cause GFR category Albuminuria Referred to as CGA Staging |
| ? | CKD is divided into 5 stages | "Stage 3" is subdivided into 3a & 3b Terminology change from "stages" to "classifications" |
| | | |

What's New?



| ALBUN | ALBUMINURIA | | | |
|---|--|--|--|--|
| KDOQI 2002 | KDIGO 2012 | | | |
| Not incorporated into the staging system | Added with 3 categories of severity: Normal to mildly increased Moderately increased Severely increased | | | |
| Previous terminology: Normoalbuminuria Microalbuminuria Macroalbuminuria | New terminology: Normal to mildly increased Moderately increased Severely increased The term "microalbuminuria" is no longer used and is discouraged | | | |
| | | | | |



Assign <u>a</u>lbuminuria* categories

CG<u>A</u> Staging

| Category | AER | ACR (Approximate equivalent) | | Terms |
|----------|--------|---------------------------------|--------|----------------------------|
| | (mg/d) | (mg/mmol) | (mg/g) | |
| A1 | <30 | <3 | <30 | Normal to mildly increased |
| A2 | 30-300 | 3-30 | 30-300 | Moderately increased* |
| A3 | >300 | >30 | >300 | Severely increased** |

Abbreviations: AER, albumin excretion rate; ACR, albumin-creatinine ratio; *Relative to young adult level.

**Including nephrotic syndrome (albumin excretion usually >22000 mg/24 hours [ACR >2220 mg/g; >220 mg/mmol])

* Note that where albuminuria measurement is not available, urine reagent strip results can be substituted



What's New?



| EVALUATION & MANAGEMENT | | | |
|--|--|--|--|
| KDOQI 2002 | KDIGO 2012 | | |
| Risk relationship between GFR and albuminuria is not defined | Risk relationship between GFR and albuminuria is defined | | |
| Frequency of monitoring and referral: Based on eGFR | Frequency of monitoring and referal: Based on eGFR and albuminuria categories | | |



CKD Consortia Data: Impact of GFR & Albuminuria on outcomes

All Cause Mortality

| | ACR <10 | ACR 10-29 | ACR 30-299 | ACR ≥300 |
|-------------|------------|--------------|---------------|-------------|
| eGFR > 105 | 1.1 | 1.5 | 2.2 | 5.0 |
| eGFR 90-105 | Ref | 1.4 | 1.5 | 3.1 |
| eGFR 75-90 | 1.0 | 1.3 | 1.7 | 2.3 |
| eGFR 60-75 | 1.0 | 1.4 | 1.8 | 2.7 |
| eGFR 45-60 | 1.3 | 1.7 | 2.2 | 3.6 |
| eGFR 30-45 | 1.9 | 2.3 | 3.3 | 4.9 |
| eGFR 15-30 | 5.3 | 3.6 | 4.7 | 6.6 |

End Stage Renal Disease

| | ACR <10 | ACR 10-29 | ACR 30-299 | ACR ≥300 | |
|---------------------------|------------|--------------|---------------|-------------|--|
| eGFR > 105 | Ref | Ref | 7.8 | 18 | |
| eGFR 90-105 | Ref | Ref | 11 | 20 | |
| eGFR 75-90 | Ref | Ref | 3.8 | 48 | |
| eGFR 60-75 | Ref | Ref | 7.4 | 67 | |
| GER USAN | 5.2 | 22 | 40 | 147 | |
| 06FR 30-45 | 56 | 74 | 294 | 763 | |
| e <mark>G</mark> TR 15-30 | 433 | 1044 | 1056 | 2286 | |

Cardiovascular Mortality

| | ACR <10 | ACR 10-29 | ACR 30-299 | |
|-------------|------------|--------------|---------------|-----|
| eGFR > 105 | 0.9 | 1.3 | 2.3 | 2.1 |
| eGFR 90-105 | Ref | 1.5 | 1.7 | 3.7 |
| eGFR 75-90 | 1.0 | 1.3 | 1.6 | 3.7 |
| eGFR 60-75 | 1.1 | 1.4 | 2.0 | 4.1 |
| eGFR 45-60 | 1.5 | 2.2 | 2.8 | 4.3 |
| eGFR 30-45 | 2.2 | 2.7 | 3.4 | 5.2 |
| eGFR 15-30 | 14 | 7.9 | 4.8 | 8.1 |

Acute Kidney Injury

| | ACR <10 | ACR 10-29 | ACR 30-299 | ACR ≥300 | |
|-------------|------------|--------------|---------------|-------------|--|
| eGFR > 105 | Ref | Ref | 2.7 | 8.4 | |
| eGFR 90-105 | Ref | Ref | 2.4 | 5.8 | |
| eGFR 75-90 | Ref | Ref | 2.5 | 4.1 | |
| eGFR 60-75 | Ref | Ref | 3.3 | 6.4 | |
| eGFR 45-60 | 2.2 | 4.9 | 6.4 | 5.9 | |
| eGFR 30-45 | 7.3 | 10 | 12 | 20 | |
| eGFR 15-30 | 17 | 17 | 21 | 29 | |

Lancet 2010 12;375:2073-81. Kidney Int 2011 79:1331-40, 79:1341-1352 & 80:93-104

Who is at risk & should be tested for CKD?

- Patients with diabetes mellitus
- Patients with hypertension
- Patients with heart failure
- Patients with atherosclerotic coronary, cerebrovascular or peripheral vascular disease
- Patients with a family history of ESRD
- Specific ethnic groups
 - First nations peoples
 - Asians and South Asians
 - Pacific Islanders/ African- Americans



Early Detection: The Premise

- Early identification of CKD will improve outcomes by identifying high risk groups, and permitting targeted therapy to be implemented so that adverse events are reduced..
 - Progression to ESRD
 - CVD events



What we know: Delay of Progression of CKD

- Reduction of BP
- Reduction of Proteinuria
- Use of ACEI
- Protein and phosphate restriction
- ? Vitamin D
- ? Erythropoietin therapy/ Anemia



Possible Events and Outcomes of Patients CKD

- Kidney Related
 - No change in GFR over time
 - Increased risk of Acute Kidney Injury
 - transient or sustained
 - Progression to dialysis/ transplantation
- Non kidney related
 - Increased risk of CVD

• Heart Failure, dysrhythmias, sudden death

increase risk of infection

increased risk of all cause mortality

Who is most likely to have progressive CKD...

- Clinical predictors of accelerated progression to ESRD
 - Proteinuria (uACR >60)
 - Hypertension
 - Diabetes
 - Race (African-American, Asian, South Asian, First nations)
 - Gender (men>women)





BC Study

Variability and Risk Factors for Kidney Disease Progression and Death Following Attainment of Stage 4 CKD in a Referred Cohort

Adeera Levin, MD, FRCPC, Ognjenka Djurdjev, MSc, Monica Beaulieu, MD, FRCPC, and Lee Er, MSc

- Observational cohort study
- Patients registered in provincial database, start observational period at GFR < 30mL/min/1.73m2, known to nephrologists
- N= 4300+ individual patients with follow up > 2 years



Variable rates of progression noted

- mean rate of change in eGFR -2.65 mL/min/1,73m²/y
- 28% had no progression
- 46% had moderate progression (1-5 mL/min/y)
- 26% had rapid progression (>5mL/min/y)





What tests?

- Blood
- Urine
- Imaging



Current eGFR equation provisos

- eGFR calculations may be less reliable in:
 - individuals with near normal GFR (>60 ml/min/1.73m²)
 - individuals with markedly abnormal body composition
 - extreme obesity
 - cachexia
 - paralysis
 - amputations
- Controversies exist as to the applicability of these formulae to

For the set of the set

Interpretation of uACR measurements

- Fluctuations common
- Repeat 2/3 samples positive
- uACR >3 but consistently less than 40 is not a cause for referral alone
- Benign (transient) causes of elevated uACR
 - Concentrated urine
 - Blood in urine (menstrual period)
 - Exercise
 - Febrile illness

Other Tests?

- · ?ANCA
- ?C3, C4
- ?Hep B, Hep C, HIV
- · ?ANA
- ?cryoglobulins





Referral is recommended f

- Acute kidney failure/ abrupt sustained change
- eGFR < 30 ml/min/1.73m². (CKD stage 4 and 5);
 contextualized within age and other parameters
- Progressive decline of eGFR not readily explained or requiring qualification
- Increasing urine protein values or active urine sediment
 - Red cell casts, RBC >20 sustained and not readily explained
- Inability to achieve treatment targets or Reassurance; explanation



Timely Referral

- Sooner than later
- Late referral has been associated with a 37% greater mortality than early referral

Archives of Internal Medicine 162 (17) 2002



- 92 yrs old
- GFR: 15, ACR: 16
- Type 2 Diabetes, +HTN



- 70 yrs
- GFR: 38, ACR: 3.0
- Post MI, no diabetes, no HTN
- Stable renal function over last 5 yrs



- 47 yr old male
- GFR: 26
- ACR: 110
- Type 2 Diabetes, HTN
- Strong FHx of ESRD





Chronic Kidney Disease is common



CKD does not usually progress to end stage disease in most patients

- Primary Care is best suited to deal with CKD and all the co-morbid problems
- Refer early when appropriate (RRT/Transplant)
- Document CKD in the Problem List Automatic Review with labs
- Dialysis is a terminal disease average life
 Compactancy is < 5yrs if no transplant!

- Avoid Nephrotoxic Drugs!
- Try new tactics to deal with the mass of Chronic Disease!

